MOBERG PHARMA AB [CBOE] overview

Moberg Pharma has secured exercise of warrants and entered into a top guarantee free of charge PR Newswire STOCKHOLM, June 11, 2024 STOCKHOLM , June 11, 2024 /PRNewswire/ -- Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has today received subscription intentions, subscription commitments and top guarantee commitments totaling approximately SEK 113.5 million , related to the warrants of series 2023:1 ("TO 2"), from a few external professional investors and the Company's largest...

Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America PR Newswire STOCKHOLM, Oct. 6, 2023 STOCKHOLM , Oct. 6, 2023 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America . The aim is to provide a pivotal part of the clinical data set for registration and commercialization of MOB-015 in the U.S.. Topline results are expected in January 2025...

Moberg Pharma and Padagis sign agreement for MOB-015 in Israel PR Newswire STOCKHOLM, Aug. 4, 2022 STOCKHOLM , Aug. 4, 2022 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has signed a distribution agreement with Padagis Israel Agencies Ltd. for MOB-015 in Israel and the Palestinian territories. Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility. Padagis will conduct...

Moberg Pharma enters into collaboration with Allderma for launch in Scandinavia PR Newswire STOCKHOLM, Nov. 8, 2021 STOCKHOLM , Nov. 8, 2021 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has entered into a collaboration with Allderma AB for the launch of MOB-015 (for nail fungus) in Sweden , Norway and Denmark . Allderma is managed by the commercial leaders which were responsible for the successful Nordic launch of Nalox ® , Moberg Pharma's first-generation nail fungus product. In the...

Moberg Pharma's Interim report for July 2019 - June 2020 to be published on August 11 - Invitation to teleconference PR Newswire STOCKHOLM, Aug. 4, 2020 STOCKHOLM , Aug. 4, 2020 /PRNewswire/ -- On August 11 th , 2020, at 08:00 am (CET) , Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - June 2020 . Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date. The teleconference will be hosted by Moberg...

The Board of Directors Exercises Authorizations to Issue and Repurchase C-shares PR Newswire STOCKHOLM, May 19, 2020 STOCKHOLM , May 19, 2020 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announced that the board of directors exercises authorizations to issue and repurchase C-shares, and converts C-shares to common shares, to secure the company's commitments under incentive programme. The extraordinary general meeting of Moberg Pharma AB (publ) on April 28, 2020 resolved - for the purpose of...

Bulletin from Moberg Pharma's AGM 2018 PR Newswire STOCKHOLM, May 15, 2018 STOCKHOLM , May 15, 2018 /PRNewswire/ -- Moberg Pharma AB's ("Company") Annual General Meeting took place on Tuesday, May 15th, 2018 in the Company´s premises in Bromma. Adoption of the income statements and the balance sheets The Annual General Meeting (the "Meeting") approved the income statements and the balance sheets for the fiscal year 2017. The Meeting resolved, in accordance with the proposal of the Board of...

Moberg Pharma AB Interim Report January - March 2018 PR Newswire STOCKHOLM, May 8, 2018 STOCKHOLM , May 8, 2018 /PRNewswire/ -- SIGNIFICANT GROWTH FOR ALL KEY BRANDS FIRST QUARTER (JAN- MAR 2018 ) Net revenue SEK 91.5 million (104.6) EBITDA SEK 21.9 million (16.7) EBITDA margin 24% (16) EBITDA for current product portfolio SEK 27.1 million (21.0) Operating profit (EBIT) SEK 12.5 million (6.9) Net profit after tax SEK 2.0 million (-3.0) Diluted earnings per share SEK 0.12 (-0.17) Operating cash...